-+ 0.00%
-+ 0.00%
-+ 0.00%

Benchmark Downgrades Biofrontera to Speculative Buy, Maintains Price Target to $3

Benzinga·05/19/2026 12:41:18
Listen to the news
Benchmark analyst Bruce D. Jackson downgrades Biofrontera (NASDAQ:BFRI) from Buy to Speculative Buy and maintains the price target from $3 to $3.